Brought to you by 
Novartis licenses Genentech's AMD candidate Lucentis
Jun 2003
Executive Summary
Novartis Ophthalmics AG licensed exclusive worldwide rights outside of N. America to Genentech's Lucentis (ranibizumab), a drug candidate in US Phase III trials for treating the wet form of age-related macular degeneration (AMD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses Genentech's AMD candidate Lucentis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice